2025 · 2nd Quarter (Apr 1 - June 30)

AMGEN

Filed by THE NICKLES GROUP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: THE NICKLES GROUP, LLC
Client: AMGEN
Filing UUID: e8d73ea0-1e13-4009-9b8e-70f5db34f0bf
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1, One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. H.R. 946 / S. 1862, ORPHAN Cures Act. Issues related to the Most Favored Nation drug pricing.

Literal federal measure citations: H.R. 1, H.R. 946, S. 1862

HCR · Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing.

CPT · Copyright/Patent/Trademark

Monitored issues related to intellectual property.

TAX · Taxation/Internal Revenue Code

H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act, and corporate taxes. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes.

Literal federal measure citations: H.R. 1990, H.R. 1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.